

SIPE
FEB 04 2005

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
17496

In Re Application:

Jane Ellen Visvader, et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/799,797	March 12, 2004	Unassigned	23389	1636	8972

Title: A METHOD OF DIAGNOSIS AND TREATMENT AND AGENTS USEFUL FOR SAME

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 Under 37 CFR 1.97(b) or 1.97(c)

Docket No.
 17496

FEB 14 2005

In Re Application: Jane Ellen Visvader, et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/799,797	March 12, 2004	Unassigned	23389	1636	8972

Title: A METHOD OF DIAGNOSIS AND TREATMENT AND AGENTS USEFUL FOR SAME

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____).

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

February 2, 2005

(Date)

Signature of Person Mailing Correspondence

Edward W. Grolz

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Dated: February 2, 2005

Edward W. Grolz

Registration No.: 33,705

SCULLY, SCOTT, MURPHY & PRESSER

400 Garden City Plaza-Ste. 300

Garden City, NY 11530

(516) 742-4343

EWG:ab

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jane Ellen Visvader, et al. **Examiner:** Unassigned
Serial No.: 10/799,797 **Art Unit:** 1636
Filed: March 12, 2004 **Docket:** 17496
For: A METHOD OF DIAGNOSIS AND
TREATMENT AND AGENTS
USEFUL FOR SAME **Dated:** February 2, 2005

Confirmation No.: 8972

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are listed on the attached Form PTO-1449, be made of record in the above-identified case.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 2, 2005.

Dated: February 2, 2005


Edward W. Grolz


1. International Publication No. WO 02/40716 A2, published May 23, 2002;
2. Visvader, Jane E., et al., "The LIM domain gene *LMO4* inhibits differentiation of mammary epithelial cells *in vitro* and is overexpressed in breast cancer", Proceedings of the National Academy of Sciences (2001), Vol. 98, No. 25, pp. 14452-14457;
3. Kenny, Daryn A., et al., "Identification and characterization of *LMO4*, an LMO gene with a novel pattern of expression during embryogenesis", Proceedings of the National Academy of Sciences (1998), Vol. 95, pp. 11257-11262;
4. Sugihara, Tod M., et al., "Mouse Deformed epidermal autoregulatory factor 1 recruits a LIM domain factor, LMO-4, and CLIM coregulators", Proceedings of the National Academy of Sciences (1998), Vol. 95, pp. 15418-15423;
5. Grutz, G., et al., "Identification of the *LMO4* gene encoding an interaction partner of the LIM-binding protein LDB1/NLI1: a candidate for displacement by LMO proteins in T cell acute leukemia", Oncogene (1998), Vol. 17, pp. 2799-2803; and
6. Tse, Eric, et al., "Characterization of the *Lmo4* gene encoding a LIM-only protein: genomic organization and comparative chromosomal mapping", Mammalian Genome (1999), Vol. 10, pp. 1089-1094.

The references were cited in an International Search Report dated November 20, 2002. Applicants are submitting copies of the cited references, together with a copy of the Search Report. The relevance of the references has been described in the Search Report.

Consideration of this Information Disclosure Statement is respectfully requested, since the art provided may be material to the examination of the present application as defined under 37 C.F.R. §1.56.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,




Edward W. Grolz

Registration No. 33,705

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza-Ste 300
Garden City, New York 11530
(516) 742-4343

EWG:nf/ab

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)



Docket Number (Optional)
17496

Application Number
10/799,797

Applicant(s)
Jane Ellen Visvader et al.

Filing Date
March 12, 2004

Group Art Unit
1636

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 02/40716 A2	5/23/02	PCT				

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	Visvader, Jane E., et al., "The LIM domain gene <i>LMO4</i> inhibits differentiation mammary epithelial cells <i>in vitro</i> and is overexpressed in breast cancer", Proceedings of the National Academy of Sciences (2001), Vol. 98, No. 25, pp. 14452-14457
	Kenny, Daryn A., et al., "Identification and characterization of <i>LMO4</i> , an LMO gene with a novel pattern of expression during embryogenesis", Proceedings of the National Academy of Sciences (1998), Vol. 95, pp. 11257-11262
	Sugihara, Tod M., et al., "Mouse Deformed epidermal autoregulatory factor 1 recruits a LIM domain factor, LMO-4, and CLIM coregulators", Proceedings of the National Academy of Sciences (1998), Vol. 95, pp. 15418-15423
	Grutz, G., et al., "Identification of the <i>LMO4</i> gene encoding an interaction partner of the LIM-binding protein LDB1/NLI1: a candidate for displacement by LMO proteins in T cell acute leukemia", Oncogene (1998), Vol. 17, pp. 2799-2803
	Tse, Eric, et al., "Characterization of the <i>Lmo4</i> gene encoding a LIM-only protein: genomic organization and comparative chromosomal mapping", Mammalian Genome (1999), Vol. 10, pp. 1089-1094

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.